KATIA CARMONA: Open Payments
NPI 1477938421 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,541 in 59 payments from 17 companies in 2025. Trend: 2023 $1,437 · 2024 $1,121 · 2025 $1,541
Food & beverage: $1,323Education: $218
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 12 | $411 |
| GENZYME CORPORATION | 6 | $234 |
| AstraZeneca Pharmaceuticals LP | 10 | $227 |
| GlaxoSmithKline, LLC. | 11 | $218 |
| Amgen Inc. | 4 | $95 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $68 |
| Azurity Pharmaceuticals, Inc. | 2 | $45 |
| Novartis Pharmaceuticals Corporation | 2 | $42 |
| Grifols USA, LLC | 1 | $34 |
| Ionis Pharmaceuticals, Inc. | 1 | $32 |
Products named: DUPIXENT, NUCALA, TEZSPIRE, AIRSUPRA, NEFFY, ALVESCO, TRELEGY ELLIPTA, Xembify.
Industry payments across FL — which companies pay providers there.
